Akademik Veri Yönetim Sistemi
Genel Tip Dergisi, cilt.35, sa.1, ss.21-30, 2025 (Scopus)
Aim: Gastric cancer, a common type of gastrointestinal (GI) system malignancy, has an incidence associated with various factors. These include ethnic background, dietary habits, socioeconomic status, lifestyle, geographic region, and the prevalence of Helicobacter pylori. As with all malignancies, the pathogenesis of gastric cancer involves various genetic factors, one of which is the human epidermal growth factor receptor-2 (EGFR-2) (Her2/neu or c-erbB2) gene. The objective of this study is to compare the amplification levels of the Her2/neu gene in gastric cancer samples obtained from our patients using Real-Time polymerase chain reaction (RT-PCR) with the overexpression of Her2 protein, assessed through immunohistochemistry (IHC) on the same tissue samples. Additionally, the study aims to investigate the relationship between Her2 positivity and prognostic factors such as age, stage, gender, tumor localization, and histological type. Method: This study was conducted prospectively on newly diagnosed 50 gastric cancer patients. Her2 gene expression at the mRNA level was assessed using RT-PCR on both tumor and normal fresh gastric tissue samples from all 50 patients. Additionally, Her2 protein levels were evaluated through IHC on paraffin blocks from these same 50 patients, and the results were compared with each other. Results: In the evaluation of IHC, Her2 overexpression was observed in five patients (10%), and Her2 amplification was detected in five patients (10%) using RT-PCR. However, it was notable that there was no correlation between these two methods, and the result was statistically insignificant (p > 0.05). Additionally, no statistically significant difference was observed between Her2 gene expression in tumor tissues and prognostic factors (p > 0.05). Conclusion: Her2 protein overexpression and Her2 gene amplification may contribute to potential tumor development. As no correlation was found between these two methods, further studies are needed to evaluate false negativity, investigate patient survival in terms of its contribution to prognosis, and validate our hypothesis.